Denecimig
Highest phase reached
Phase 2
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Antibody
- Drug name
- Denecimig
- denecimig
- Denecimig
- denecimig [INN]
- DENECIMIG [USAN]
- denecimig inn
- denecimig usan
- factor viiia mimetic
- Factor VIIIa-mimetic
- fviii mimetic
- FVIII Mimetic
- Immunoglobulin G4 [230-proline,de-449-lysine], anti-(human blood-coagulation factor IX)(human clone 0365-0001-9985 γ4-chain), disulfide with human clone 0365-0001-9985 κ-chain, (228→226′),(231→229′)-bis(disulfide) with anti-(human blood-coagulation factor X) immunoglobulin G4 [228-proline,405-leucine,409-lysine,de-447-lysine] (human clone 0365-0001-8174 γ4-chain) disulfide with human clone 0365-0001-8174 κ-chain
- immunoglobulin g4 230 proline de 449 lysine anti human blood coagulation factor ix human clone 0365 0001 9985 γ4 chain disulfide with human clone 0365 0001 9985 κ chain 228 226 231 229 bis disulfide with anti human blood coagulation factor x immunoglobulin g4 228 proline 405 leucine 409 lysine de 447 lysine human clone 0365 0001 8174 γ4 chain disulfide with human clone 0365 0001 8174 κ chain
- mim 8
- MIM-8
- mim8
- Mim8
- nn 7769
- NN-7769
- nn7769
- NN7769
- nnc 0365 3769
- NNC-0365-3769
- nnc0365 0005 3769
- nnc0365 3769
- NNC0365-0005-3769
And 3 more, listed on the interactive page.
- CAS registry numbers
- 2488745-86-2
- ChEMBL ID
- CHEMBL5314670
- FDA ingredient codes (UNII)
- EUV85RR8DJ
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -mig
Investigated indications
- Condition
- Hemophilia A
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0010602
- Subject identifier
- D006467
Open Targets indications
- Condition identifier
- MONDO_0010602
- Highest recorded phase
- 3
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Glycosylation sites (N)
- Sequence
- 299 $ 297'
- Component
- Heavy chain: anti-F9(H)
- Type
- Protein
- Sequence
- EVQLVESGGGLVQPGRSLRLSCAASGFTFHDYAMHWVRQVPGKGLEWVSGISWRGDIGGYVKSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCVKSYGSGSFYNAFDSWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG
- Component
- Disulfide bridges
- Sequence
- 22-96 $ 22''-96'' $ 23'-88' $ 23'''-89''' $ 134'-194' $ 134''-216''' $ 136'''-196''' $ 136-214' $ 147''-203'' $ 149-205 $ 228-226'' $ 231-229'' $ 261''-321'' $ 263-323 $ 367''-425'' $ 369-427
- Component
- Light chain: anti-F10(L''')
- Type
- Protein
- Sequence
- EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGQSSRTRGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFGDSQLFTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
- Component
- Heavy chain: anti-F10(H'')
- Type
- Protein
- Sequence
- EVQLVQSGAEVKKPGESLRISCKGSGYSFSTSWIVWVRQMPGKGLEWMGMIDPSDSFTSYSPSFQGHVTISADKSISTAYLQWSSLKASDTAMYYCARLHYYNSEEFDVWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFLLYSKLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG
- Component
- Light chain: anti-F9(L')
- Type
- Protein
- Sequence
- DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKFLIYKASKLERGTPSRFSGSGSGTEFSLTISSLQPDDFATYYCLEYSSYIRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Related records
Trials (13)
- A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors
- A Research Study Investigating Mim8 in People With Haemophilia A
- A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5)
- A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
- A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors
- A Study to Compare the Blood Levels of Mim8 in Healthy Men When Administered With the DV3407-C1 Pen Injector or a Syringe and Cartridge
- Development and Validation of a Sputum Biomarker mRNA Panel for the Diagnostic Work-up of Asthma 3
- Efficacy and Safety of Linggui Yangyuan Paste in Patients With Male Infertility
- Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC)
- Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma
- Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
- The Efficacy and Safety of Ginkgo Biloba Dropping Pills in the Treatment of Coronary Heart Disease With Stable Angina Pectoris and Depression
- Yiqi Wenjing Prescriptions Preventive Efficacy of Oxaliplatin-induced Peripheral Neuropathy Clinical Trial
In development for (1)
- Hemophilia A Phase 1